PureTech Health (LON:PRTC) Stock Price Passes Below Two Hundred Day Moving Average – Time to Sell?

Posted by George Bondi on Aug 8th, 2026

PureTech Health plc (LON:PRTC – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 126.05 and traded as low as GBX 114. PureTech Health shares last traded at GBX 117.40, with a volume of 3,148,794 shares trading hands.

Wall Street Analyst Weigh In

Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 508 price objective on shares of PureTech Health in a report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of GBX 508.

View Our Latest Report on PRTC

PureTech Health Stock Up 0.7%

The company has a market capitalization of £285.77 million, a price-to-earnings ratio of -2.55 and a beta of 0.77. The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33. The business has a 50-day moving average price of GBX 125.17 and a 200-day moving average price of GBX 126.05.

Insider Transactions at PureTech Health

In related news, insider John LaMattina acquired 93,944 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were purchased at an average price of GBX 1 per share, for a total transaction of £939.44. Also, insider Sharon Barber-Lui acquired 93,944 shares of PureTech Health stock in a transaction on Wednesday, July 29th. The shares were purchased at an average cost of GBX 1 per share, with a total value of £939.44. Insiders have bought a total of 617,569 shares of company stock worth $18,063,751 in the last three months. Insiders own 13.41% of the company’s stock.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.